Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)

Fig. 3

Dosage regimen (unblinded period). Investigators will administer the first dose of IDEC-C2B8 within 14 days after the date of allocation (the date the first dose of IDEC-C2B8 is administered is set as Unblinded Day 1). IDEC-C2B8 will be administered via two 375-mg/m2 doses (maximum dose: 500 mg) separated by 1 week (Unblinded Days 1 and 8)

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us